Volume 10, Number 2Meeting ReviewsChronic Prostatitis/Chronic Pelvic Pain Syndrome: Finding a Way Forward in the United KingdomMeeting ReviewJ Curtis NickelMarina CameronMeesha PatelReport from the First United Kingdom Symposium on Chronic Prostatitis, January 30, 2008, London, United Kingdom [Rev Urol. 2008;10(2):160-163]ProstateChronic pelvic pain syndromeProstatitisPainPsychosocial aspects of painAlternative treatments
Volume 13, Number 3Review ArticlesRole of Inflammation in Benign Prostatic HyperplasiaDisease State ReviewSteven A KaplanRichard LeeBilal ChughtaiAlexis E TeInflammation of the prostate may represent a mechanism for hyperplastic changes to occur in the prostate. There are a variety of growth factors and cytokines that may lead to a proinflammatory process within the prostate. There are several proposed mechanisms that lead to both the intrinsic and extrinsic basis of inflammation. Prostatic inflammation may represent an important factor in influencing prostatic growth and progression of symptoms. This article reviews the recent literature on inflammation leading to chronic prostatic diseases, such as benign prostatic hyperplasia. [Rev Urol. 2011;13(3):147-150 doi: 10.3909/riu0535] © 2011 MedReviews®, LLCBenign prostatic hyperplasiaInflammationProstatitisProstatic cytokinesVitamin D
Volume 14, Number 3Book Reviewsa-Blockers for the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome: An Update on Current Clinical EvidenceTreatment UpdateJ Curtis NickelNaji ToumaThe pathogenesis of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is multifactorial, making its treatment difficult. Multimodal therapy including a- adrenergic antagonists (a-blockers), anti-inflammatory agents, and other pain treatments may provide optimal management for CP/CPPS. Although a-blockers are the most prescribed drugs for patients with CP/CPPS, not all studies support their efficacy. A recent meta-analysis of small trials suggested that treatment with a-blockers, possibly in combination with antibacterial agents, is efficacious in relieving symptoms. Third-generation a1A blockers (silodosin, tamsulosin) may provide efficacy as well as reduced cardiovascular side effects. Future research should aim to identify potential biomarkers associated with treatment response. [Rev Urol. 2012;14(3/4):56-64 doi: 10.3909/riu0557] © 2013 MedReviews®, LLCAdrenergic alpha-1 receptor antagonistsTamsulosinSilodosinAlfuzosinProstatitis